Amneal Suffers Setback On US Cinacalcet
Non-Infringement Of Amgen Sensipar Formulation Patent Overturned
Executive Summary
The US Court Of Appeals has told a Delaware district court to think again on whether Amneal’s generic cinacalcet formulation infringes Amgen’s Sensipar formulation patent. The court also said Zydus Cadila infringed, but Piramal did not.